AMENDMENTS TO THE CLAIMS

Claims 25 and 34-42 are pending in the application.

Claims 1-24 (canceled).

25. (Currently amended) A method of treating a patient suffering from psoriasis ~~comprising~~ consisting the step of administering to the patient a pharmaceutical formulation comprising an antibody that binds to interleukin 12.

Claims 26-33 (canceled).

34. (Previously presented) The method according to Claim 25, wherein said antibody is in an amount effective to block the effect of interleukin 12.

35. (Previously presented) The method according to Claim 25, wherein said antibody is a monoclonal antibody.

36. (Previously presented) The method according to Claim 35, wherein said monoclonal antibody has a binding affinity of at least 10^8 M^{-1}.

37. (Previously presented) The method according to Claim 35, wherein said monoclonal antibody is a chimeric monoclonal antibody or a humanized monoclonal antibody.

38. (Previously presented) The method according to Claim 37, wherein said monoclonal antibody is 5F2, 16F2, 16G2, or 20E11 in a chimeric or humanized form.

39. (Previously presented) The method according to Claim 25, wherein said pharmaceutical formulation is administered to the patient orally, topically, subcutaneously, intramuscularly, or intravascularly.

40. (Previously presented) The method according to Claim 25, wherein said antibody is administered in a dose of 0.01-100 mg/kg body weight.

41. (Previously presented) The method according to Claim 40, wherein said antibody is administered in a dose of 0.1-10 mg/kg body weight.

42. (Previously presented) The method according to Claim 25, wherein said treatment reduces PASI by at least 50%.

Claims 43-44 (canceled).